Syn2bio (WAR:S2B) EBIT per Share: zł (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
11 GF Score
Price zł81.40
! 2 Warning Signs
View Full Analysis

What is Syn2bio EBIT per Share?

Syn2bio WAR:S2B +1.88% 11 EBIT per Share is zł as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,173 Biotechnology companies, Syn2bio ranks worse than 85251.41% on this metric.

Syn2bio's EBIT per Share for the six months ended in Sep. 2025 was zł-3.31. Syn2bio does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Syn2bio's EBIT per Share or its related term are showing as below:

WAR:S2B's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Syn2bio's EBIT for the six months ended in Sep. 2025 was zł-28.92 Mil.

Syn2bio  (WAR:S2B) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Syn2bio EBIT per Share Related Terms

Syn2bio EBIT per Share Historical Data

* Premium members only.

The historical data trend for Syn2bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio EBIT per Share Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
EBIT per Share
-1.60 -2.28 -3.31

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
EBIT per Share -1.60 -2.28 -3.31
WAR:S2B
11GF Score
Syn2bio SA WAR:S2B
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Syn2bio's EBIT per Share for the fiscal year that ended in Sep. 2025 is calculated as

EBIT per Share(A: Sep. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-28.923/8.729
=-3.31

Syn2bio's EBIT per Share for the quarter that ended in Sep. 2025 is calculated as

EBIT per Share(Q: Sep. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-28.923/8.729
=-3.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of zł mean?
Syn2bio (WAR:S2B) has a EBIT per Share of zł as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Syn2bio and its competitors. According to the industry distribution chart, Syn2bio ranks #999999 out of 1173 companies in the Biotechnology industry.
Is Syn2bio's EBIT per Share too high?
Syn2bio's current EBIT per Share is zł. Based on the distribution chart, Syn2bio ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syn2bio has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn2bio ranks #999999 out of 1173 companies for EBIT per Share. This places Syn2bio in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Syn2bio and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syn2bio's current EBIT per Share is zł. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current EBIT per Share of zł. The current EBIT per Share is zł. Syn2bio's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current EBIT per Share is zł as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
11GF Score

Get the complete analysis for WAR:S2B

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł81.40
Price